Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Located in Northbrook, Illinois, the company serves as the headquarters for the U.S. More than 3,000 Astellas employees are based in the U.S. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Our commitment to changing tomorrow is measured not only by our focus on bringing innovative and effective new medicines to patients and physicians, but also by the importance we place on the impact we can make within the communities where we work and live. Astellas supports many causes and has created Changing Tomorrow Day, an annual, worldwide volunteer event, to demonstrate this commitment.

Astellas US Headquarters

1 Astellas Way
Northbrook, IL 60062-6111
Phone: 800-888-7704

President, Astellas US
Percival Barretto-Ko

Employees Based in the US
More than 3000

U.S. Product Sales:
$4.1 Billion* (FY 2019)
*Accurate as of April 2020. 

Click here for more Astellas locations

R&D Pipeline

To learn more about the progress of Astellas' clinical development projects, visit the Overview of R&D Pipeline on the Astellas Pharma Inc. website.

Major Corporate Highlights

2005 - Established U.S. headquarters near Chicago, Illinois, with the merger of Yamanouchi & Fujisawa.

2008 - Established a new U.S.-based subsidiary, Astellas Pharma Global Development, Inc., which acts as the headquarters for global development.

2010 - Astellas acquires New York-based OSI to support new focus on oncology.

2012 - More than 1,000 employees relocate to new U.S. headquarters in Northbrook, Illinois.

2016 - Astellas acquires Ocata Therapeutics, Marlboro, Mass., and establishes the Astellas Institute for Regenerative Medicine (AIRM).

2017 - Astellas opens new drug discovery and development hub in San Diego, Calif, Astellas Research Institute of America (ARIA).

2017 - Astellas acquires Mitobridge, Inc., Cambridge, Massachusetts to discover and develop compounds that target mitochondrial function.

2018 - Astellas acquires Universal Cells, Inc., Seattle Washington, to develop stem cell therapies.

2018 - Astellas acquires Potenza Therapeutics, Inc., Cambridge MA to build a portfolio of novel immuno-oncology therapies

2019 - Astellas acquires Xyphos Biosciences, Inc. to add talent and a proprietary therapeutic platform to accelerate next-generation cancer immunotherapy

2020 - Astellas acquires Audentes Therapeutics, Inc. to become a global leader in AAV-based genetic medicines

2020 - Astellas and Adaptimmune Therapeutics plc, Philadelphia, Penn. and Oxfordshire, UK, entered into agreement for T-cell therapies for people with cancer

Corporate Recognition Awards

Astellas has been recognized as an employer of choice by Forbes and Working Mother magazines, on Corporate Knights 100 Most Sustainable Companies Rankings, as a Great Place to Work in the Pharma Industry, and on the Human Rights Campaign’s Corporate Equality Index. To learn more, visit our Awards & Recognition section.